Incyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology Congress 2026
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Incyte Data at the European Academy of Dermatology and Venereology Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio
Incyte Announces Funding of MINJUVI® for patients with Relapsed or Refractory Follicular Lymphoma through Ontario's FAST Program
Opzelura® Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
Incyte Presents Phase 1/2 Multidose Data for VGA039 at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
QIMC Further Derisks Nova Scotia Natural Hydrogen Multi-Gas System with New Thermogenic Gas and Helium Results
Flow Metals Secures Little Gold Creek Headwaters, Completing Strategic Consolidation of Sixtymile Gold District
Highlights Include Iron Values Exceeding 30%, Nickel up to 500 ppm, Cobalt up to 187 ppm and Vanadium up to 1,710 ppm
